Corvus Pharmaceuticals

CRVS

Market cap $630M

8.43 USD

+0.38

4.72%

At close Updated Dec 3, 10:43 AM EST

1 day

4.72%

5 days

-4.53%

1 month

9.77%

3 months

50%

6 months

104.61%

Year to date

55.25%

1 year

1.81%

5 years

114.5%

10 years

-40.84%

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31

Healthcare Biotechnology